Eylea (aflibercept) Letter of Medical Necessity
Eylea (aflibercept) prior authorization is often challenged because off-label bevacizumab (Avastin) is dramatically cheaper. LMNs should address prior anti-VEGF response or specific patient factors.
FDA-Approved Indications
- ● neovascular AMD
- ● macular edema following RVO
- ● diabetic macular edema
- ● diabetic retinopathy
- ● retinopathy of prematurity
Why Eylea Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Avastin (off-label) preferred
- 2. Indication not specified
- 3. Visual acuity baseline missing
- 4. OCT findings not documented
What to Include in a Eylea Letter of Medical Necessity
Document indication, baseline visual acuity, OCT findings, prior anti-VEGF trials and response, fluid status, and clinical rationale for aflibercept selection.
Key clinical evidence to cite:
- ✓ VIEW 1/2, VIVID, VISTA, COPERNICUS, GALILEO
Relevant guidelines:
- 📖 AAO Preferred Practice Patterns
Eylea Prior Authorization Criteria
Standard criteria across major US payers for Eylea. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Eylea
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Eylea Prior Authorization FAQ
Why was my Eylea prior authorization denied?
The most common denial reasons for Eylea are: Avastin (off-label) preferred; Indication not specified; Visual acuity baseline missing; OCT findings not documented.
What should a Eylea Letter of Medical Necessity include?
Document indication, baseline visual acuity, OCT findings, prior anti-VEGF trials and response, fluid status, and clinical rationale for aflibercept selection.
Which payers cover Eylea?
Eylea is covered by major US payers including Medicare Part B, UnitedHealthcare, Aetna, Cigna, BCBS, though formulary tier and prior authorization criteria vary.